GlaxoSmithKline: Meningococcal Infections trials

The registry lists 71 Meningococcal Infections studies with GlaxoSmithKline as lead sponsor. 0 are open to participants now and 60 have results posted.

Phase 1 2Phase 2 26Phase 3 34Phase 4 6No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study on the Safety, Tolerability and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy InfantsCompletedNCT05082285Phase 2Results posted
• A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and AdultsCompletedNCT04886154Phase 1/2Results posted
• Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY VaccineCompletedNCT04707391Phase 3Results posted
• Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young AdultsCompletedNCT04502693Phase 3Results posted
• Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine When Administered Concomitantly With GSK Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of AgeCompletedNCT04318548Phase 3Results posted
• A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adults 18 to 40 Years of AgeCompletedNCT03652610Phase 2Results posted
• Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy InfantsCompletedNCT03621670Phase 3Results posted
• A Sourcing Study to Collect Human Blood Samples From Healthy AdultsCompletedNCT03493919Phase 4Results posted
• A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adolescents and Young Adults 10 to 40 Years of AgeCompletedNCT03433482Phase 2Results posted
• Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY VaccinationCompletedNCT02986854Phase 3Results posted
• Study to Assess the Immunological Long-term Persistence of Antibodies (Abs) 2 Years After GlaxoSmithKline (GSK) Meningococcal ABCWY Vaccination in the V102_15 (NCT02212457) and Response to a Booster in AdolescentsCompletedNCT02946385Phase 2Results posted
• Safety of 4CMenB Exposure During PregnancyCompletedNCT02640677Results posted
• Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate VaccineCompletedNCT02639351Phase 1Results posted
• A Study to Evaluate 4-year Antibody Persistence and Booster Response Following MenABCWY Vaccination in Healthy Adolescents and Young Adults Who Previously Participated in Studies V102_02 (NCT01210885) and V102_02E1 (NCT01367158)CompletedNCT02451514Phase 2Results posted
• Combined Study - Phase 3b MenB Long Term Persistence in AdolescentsCompletedNCT02446743Phase 3Results posted
• Evaluation of Antibody Persistence Following 4 MenACWY VaccinationsCompletedNCT02446691Phase 4Results posted
• Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Infant StudyCompletedNCT02287688Results posted
• Assessing the Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy AdolescentsCompletedNCT02285777Phase 2Results posted
• Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy RegistryCompletedNCT02223637Results posted
• Trial to Assess Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in AdolescentsCompletedNCT02212457Phase 2Results posted
• Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan.CompletedNCT02173704Phase 3Results posted
• Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B Vaccine When Administered Concomitantly With GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy InfantsCompletedNCT02106390Phase 3Results posted
• Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary VaccinationCompletedNCT01777308Phase 3Results posted
• Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Conjugate Vaccine (GSK134612) When Co-administered With Boostrix® in Subjects Between 11 and 25 Years of AgeCompletedNCT01767376Phase 3Results posted
• Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects From 2 Months to 55 Years of Age in the Republic of South KoreaCompletedNCT01766206Phase 4Results posted
• Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young AdultsCompletedNCT01755689Phase 3Results posted
• Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age.CompletedNCT01682876Phase 3Results posted
• Comparison of GlaxoSmithKline (GSK)134612 in Subjects With Increased Risk for Meningococcal Disease Versus Healthy SubjectsCompletedNCT01641042Phase 3Results posted
• Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Conjugate Vaccine When Co-administered With Routine Vaccines in Healthy Infants and ToddlersCompletedNCT01340898Phase 3Results posted
• Persistence and Booster Study of GSK Biologicals' Meningococcal Vaccine (GSK134612) in Healthy ChildrenCompletedNCT01266993Phase 3Results posted
• Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine Given as One Dose to Healthy Subjects Above 56 YearsCompletedNCT01235975Phase 3Results posted
• Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/AdultsCompletedNCT01165242Phase 2Results posted
• Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Versus Mencevax™ ACWY in Healthy 18-25 Year OldsCompletedNCT01154088Phase 3Results posted
• Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib VaccinesCompletedNCT01144663Phase 3Results posted
• Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK 134612CompletedNCT00974363Phase 3Results posted
• Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK134612CompletedNCT00955682Phase 3Results posted
• Co-administration of Meningococcal Vaccine GSK134612 and Pneumococcal Vaccine GSK1024850A vs Individual AdministrationCompletedNCT00758264Phase 3Results posted
• The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy ToddlersCompletedNCT00718666Phase 2Results posted
• The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Adolescents/AdultsCompletedNCT00715910Phase 2Results posted
• Comparison of GSK Biologicals' Meningococcal Vaccine (GSK134612) and Licensed MenC-CRM197 Vaccine in Healthy ChildrenCompletedNCT00674583Phase 3Results posted
• Comparison of GSK134612 in Subjects Previously Vaccinated Against Meningococcal Disease Versus Non-vaccinated SubjectsCompletedNCT00661557Phase 2Results posted
• Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014CompletedNCT00614614Phase 3Results posted
• Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 2-10 Year Old SubjectsCompletedNCT00514904Phase 3Results posted
• Co-Administration of Meningococcal Vaccine GSK134612 With Infanrix Hexa™ Versus Individual Administration of Each VaccineCompletedNCT00508261Phase 3Results posted
• Prophylactic Antipyretic Treatment in Children Receiving Booster Dose of Pneumococcal Conjugate Vaccine GSK1024850ACompletedNCT00496015Phase 3Results posted
• Safety & Immunogenicity Study of Meningococcal Vaccine GSK134612 Given With Priorix-Tetra™ to 12-23 Month-Old ChildrenCompletedNCT00474266Phase 3Results posted
• Immunogenicity and Safety of Meningococcal Vaccine GSK134612 Given as 1 or 2 Doses to Healthy 9-12 Months Old Toddlers.CompletedNCT00471081Phase 2Results posted
• Primary Study to Demonstrate Non-inferiority and Immunogenicity of GSK Biologicals' Meningococcal Vaccine 134612CompletedNCT00465816Phase 3Results posted
• Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 11-17 Year-Old SubjectsCompletedNCT00464815Phase 3Results posted
• Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same VaccinesCompletedNCT00463437Phase 3Results posted
• Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years.CompletedNCT00454909Phase 2Results posted
• Lot Consistency, Immuno, Safety of Meningococcal Vaccine GSK134612 Given With Fluarix™ to 18-55 Year-Old AdultsCompletedNCT00453986Phase 3Results posted
• Study in Children to Evaluate Non-Inferiority and Persistence up to 5 Years of GSK Bio Meningococcal Vaccine 134612CompletedNCT00427908Phase 2Results posted
• Study in Adolescents/Adults to Evaluate Non-inferiority&Persistence up to 5 Years of GSK Bio MenACWY Conjugate VaccineCompletedNCT00356369Phase 2Results posted
• Study to Asses DTPw-HBV/Hib at 15-18 Months (m) and Mencevax™ ACW at 24 to 30 m in Primed SubjectsCompletedNCT00317109Phase 3Results posted
• Immune Response & Safety of GSK Biologicals' Mencevax™ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 StudyCompletedNCT00291343Phase 3Results posted
• Safety of Purified Meningococcal Vaccine With Serogroups ACWY, in 3,000 Filipino Subjects Aged > 2 YearsCompletedNCT00290329Phase 4Results posted
• Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate VaccineCompletedNCT00289783Phase 3Results posted
• Safety & Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5 Years OldCompletedNCT00196976Phase 2Results posted
• Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal VaccineCompletedNCT00129129Phase 2Results posted
• A Study on the Immune Response and Safety of a Vaccine Against N. Meningitidis Serogroup B Infection in Healthy Infants From 2 Months of AgeActive, not recruitingNCT06113198Phase 4
• N. Meningitidis Carriage StudyCompletedNCT01808365
• Study in Adolescents/Adults to Evaluate the Persistence up to 3.5 Yrs of GSK Biologicals Meningococcal Vaccine 134612CompletedNCT00390143Phase 2
• Assess the Non-inferiority of GSK Biologicals' Mencevax™ ACWY (Manufactured by a New Process) vs Mencevax™ ACWY (the Already Existing Vaccine in the Market) When Given as a Single Dose to Subjects Aged 2-30 YrsCompletedNCT00227422Phase 4
• Evaluate 4 Different Formulations of Meningococcal Serogroups A, C, W-135, Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 15-19 YrsCompletedNCT00196963Phase 2
• Study to Evaluate Meningococcal Serogroups A,C,W-135,Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 18-25 YearsCompletedNCT00196950Phase 2
• Immunogenicity & Safety Study of a Meningococcal Serogroup B Vaccine Given in a 3 Dose Schedule to Healthy Adolescents Aged 12-18 YrsCompletedNCT00137917Phase 2
• Study to Evaluate GlaxoSmithKline (GSK) Biologicals' MenC-TT and Hib-MenC-TT or Meningitec™ in Healthy ToddlersCompletedNCT00135564Phase 2
• Study to Evaluate GlaxoSmithKline (GSK) Biologicals' MenC-TT Vaccine and Hib-MenC-TT Vaccine in InfantsCompletedNCT00135486Phase 2
• Study in Children to Evaluate the Immunogenicity and Safety of 4 Formulations of GSK Bio MenACWY-TT Conjugate VaccineCompletedNCT00126984Phase 2
• Evaluate 4 Different Formulations of Meningococcal Serogroups A,C,W-135,Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 15-19 YrsCompletedNCT00126945Phase 2